{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-033887","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.856747+00:00","generated_at":"2026-06-21T12:20:21.653156+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos receives Nasdaq deficiency notice for late Q3 10-Q; expects to file in weeks","bullets":["Nasdaq notified Vivos of non-compliance with Listing Rule 5250(c)(1) for late Q3 2022 Form 10-Q.","This is the second delinquency; Q2 2022 filing was also late and previously disclosed.","Company expects to submit a compliance plan to Nasdaq allowing until February 20, 2023 to regain compliance.","Revenue recognition issues (ASC 606) have been resolved; Q1 2022 10-Q restated on November 25, 2022.","Vivos plans to file both Q2 and Q3 2022 10-Qs in the coming weeks, which would cure the deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-033887","json":"https://secwatch.observer/filing/0001493152-22-033887.json","markdown":"https://secwatch.observer/filing/0001493152-22-033887.md","text":"https://secwatch.observer/filing/0001493152-22-033887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222033887/0001493152-22-033887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222033887/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:20:21.653156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d2333708a0162dfee2e2a793d7ecabc3cf51e50","claim":"Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"November 16, 2022, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-Q for the quarter ended September 30, 2022, the Company no longer complies with the Nasdaq Listing Rules for continued listing under Rule 5250(c)(1) (the “Periodic Filing Requirement”). Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. As reported in a press release dated August 26, 2022, the Company previously received a d","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222033887/0001493152-22-033887-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}